Brazil’s August 2026 diabetes guidelines expand the roles of both semaglutide and tirzepatide, with semaglutide receiving additional cardiovascular and kidney recommendations
diretriz.diabetes.org.br/diretriz-para-tratam...Posted Aug 30, 2026, 11:57 AM UTC
80